PO.PS01.08 · 人群科学
解析不同发病率国家中食管癌的促进决定因素
Deciphering the promotional determinants of esophageal cancer in countries with varying incidence
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
食管鳞状细胞癌(ESCC)的发病率在全球范围内差异巨大,与已知危险因素如酒精、吸烟和热饮的暴露相关。传统上一直假设此类暴露通过直接或间接引起DNA突变而导致细胞恶性转化。然而,最近的证据表明,大多数ESCC危险因素并不引起独特的突变谱,提示这些致癌物可能作为非诱变性的肿瘤促进因子起作用。本研究旨在探究外源性暴露在促进正常食管组织中预启动细胞克隆扩增、进而导致ESCC中的作用。
为此,我们正在检查来自中国、伊朗、马拉维、南非、俄罗斯、巴西和加拿大九个地理区域的ESCC患者和非癌症供体的200份食管上皮样本的克隆结构,这些区域的年龄标准化ESCC发病率从每10万人1例到84例不等。可获得详细的人口学、生活方式和暴露信息,包括烟草、酒精和热饮。食管上皮组织经解剖后,通过NanoSeq进行突变特征和突变负荷评估,并通过500x全外显子组测序识别处于正向选择下的突变基因。空间蛋白质组学和转录组学分析正在进行中,以描绘癌前细胞及其微环境生态位的表型。
对来自高风险和中风险区域97例病例的初步分析揭示了酒精和烟草对正常食管组织的强烈诱变效应。酒精相关的突变特征SBS16和ID11在73%的饮酒者(22/30)中被检出,并在同时暴露于酒精和烟草的病例中富集。相比之下,热饮消费与独特的突变谱无关。对47例具有可用WES数据病例的dN/dS分析识别出11个处于正向选择下的基因,包括NOTCH1、TP53、FAT1和PPM1D。暴露于烟草的病例在这些癌症基因中的若干个上表现出更高比例的突变上皮。值得注意的是,NOTCH1突变上皮的比例与ESCC发病率呈反向关联,提示在高风险人群中携带这一保护性突变的克隆有所减少。
这些发现揭示了ESCC发生中诱变过程与促进过程之间的复杂相互作用,并为已知和可疑危险因素在克隆选择中的作用提供了见解。这项工作可能最终指导针对食管致癌最早期阶段的预防策略。
查看英文原文 English abstract
Esophageal squamous cell carcinoma (ESCC) incidence varies widely across the world, correlating with exposure to known risk factors like alcohol, smoking, and hot liquids. It has traditionally been assumed that such exposures lead to malignant cell transformation by directly or indirectly causing DNA mutations. However, recent evidence revealed that most ESCC risk factors do not elicit distinct mutation profiles, suggesting that these carcinogens may act as non-mutagenic tumor-promoting agents. This study aims to investigate the role of exogenous exposures in promoting the clonal expansion of pre-initiated cells in normal esophageal tissue, leading to ESCC.
To address this, we are examining the clonal structure of 200 esophageal epithelium samples from ESCC patients and non-cancer donors across nine geographical regions in China, Iran, Malawi, South Africa, Russia, Brazil, and Canada, with age-standardized ESCC incidence rates ranging from 1 to 84 per 100,000. Detailed demographic, lifestyle, and exposure information, including tobacco, alcohol, and hot liquids, is available. Esophageal epithelial tissues are dissected and analyzed by NanoSeq for mutational signature and mutation burden evaluation, and by 500x whole-exome sequencing to identify mutant genes under positive selection. Spatial proteomics and transcriptomics are ongoing to profile the phenotype of premalignant cells and their microenvironment niches.
Preliminary analyses of 97 cases from high- and intermediate-risk regions revealed a strong mutagenic effect of alcohol and tobacco on normal esophageal tissue. Alcohol-related mutational signatures SBS16 and ID11 were detected in 73% of drinkers (22/30), and were enriched in cases exposed to both alcohol and tobacco. In contrast, hot liquid consumption was not related to distinct mutation profiles. dN/dS analysis in 47 cases with available WES data identified 11 genes under positive selection, including NOTCH1 , TP53 , FAT1 , and PPM1D . Cases exposed to tobacco presented higher fractions of mutated epithelia in several of these cancer genes. Notably, the fraction of NOTCH1 -mutant epithelia was inversely associated with ESCC incidence, suggesting a reduction of clones harboring this protective mutation in high-risk populations.
These findings shed light on the complex interplay between mutagenic and promotional processes in ESCC development and provide insights into the role of known and suspected risk factors in clonal selection. This work may ultimately guide preventive strategies targeting the earliest stages of esophageal carcinogenesis.
利益披露 Disclosure
L. Torrens, None..
R. Blanco, None..
J. C. Fowler, None..
A. de Carvalho, None..
B. Abedi-Ardekani, None..
V. Gaborieau, None..
P. Chopard, None..
C. Carreira, None..
A. Gonzalez, None..
J. Reina, None..
A. Martinez-Casals, None..
A. Jensen, None..
R. M. Reis, None..
A. Fazel, None..
M. Parker, None..
D. Zaridze, None..
P. Ashton-Prolla, None..
M. P. Curado, None.
M. Nilsson,
CARTANA co-founder.
E. Lundberg,
Chan-Zuckerberg Initiative Foundation, Element Biosciences, Cartography Biosciences, Pfizer, GenBio.AI, and Pixelgen Technologies AB Advisor.
P. H. Jones, None..
N. Lopez-Bigas, None..
P. Brennan, None.